Real-World Survival Outcomes of Adjuvant Chemotherapy Versus Endocrine Therapy Alone in Hormone Receptor- Positive, Human Epidermal Growth Factor Receptor 2-Negative Invasive Lobular Carcinoma

Objective

This study aimed to compare disease-free survival (DFS) and overall survival (OS) between patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative invasive lobular carcinoma (ILC) who received adjuvant chemotherapy plus endocrine therapy and those who received adjuvant endocrine therapy alone in a real-world setting.